Patients with core binding factor [CBF] AML, inversion 16 or t(8;21), have traditionally been considered as “favorable risk” AML with disease relapse in “only” 40–50% of patients treated with chemotherapy alone. This evidence concerns the gene CEBPZ and acute myeloid leukemia.